Janssen pays $10m upfront to license technology for Nucynta ER from Depomed
This article was originally published in Scrip
Depomed will earn $10 million upfront and low single-digit royalties through the end of 2021 on sales of Nucynta ER (tapentadol extended-release tablets) in the US, Canada and Japan under an agreement with Janssen Pharmaceuticals for a non-exclusive license and certain other rights to patents for Depomed's Acuform gastric retentive drug delivery technology.
You may also be interested in...
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.